Aesthetic
Medical Market News; RepliCel (OTCQB: $REPCF) (TSXV: $RP) Reports US Patent
Issued for Novel Dermal Injection Technologies
"We
are confident RepliCel's extensive patent estate for its cell therapy and
injection devices will provide our products with long-term market
exclusivity," -Lee R. Buckler, CEO
VANCOUVER,
BC - April 26, 2017 (Investorideas.com Newswire) Aesthetic Medical Market News
alert ; RepliCel Life
Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel"
or the "Company"), a clinical stage regenerative medicine company
developing cell therapies for aesthetic and orthopedic conditions, today
announced the granting of a key patent in the United States (U.S. Patent No.
9,616,182) covering significant components of the Company's novel, multi-needle
dermal injection device.
No comments:
Post a Comment